Noninvasive detection of circulating tumor DNA for disease classification and monitoring in patients with brain tumors.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00015307

Enrollment

200

Registered

2018-08-27

Start date

2018-08-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C71 C72

Interventions

Group 1: ctDNA profiling pretreatment, during therapy, and at post treatment time points.

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with suspected brain cancer or diagnosed with brain cancer

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
PFS difference based on ctDNA positivity after initial treatment, measured by sequencing methods	—

Secondary

Measure	Time frame
OS difference based on ctDNA positivity after initial treatment, measured by sequencing methods	—

Countries

Germany

Contacts

Public ContactFlorian Scherer

Universitätsklinikum Freiburg

florian.scherer@uniklinik-freiburg.de076127071822

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026